Decreased cathepsin V expression due to fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis

Rheumatology (United Kingdom)

Volumn 52, Issue 5, 2013, Pages 790-799

  Noda, Shinji ^a   Asano, Yoshihide ^a   Takahashi, Takehiro ^a   Akamata, Kaname ^a   Aozasa, Naohiko ^a   Taniguchi, Takashi ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Sumida, Hayakazu ^a   Kuwano, Yoshihiro ^a   Yanaba, Koichi ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; Cathepsin V; Fibrosis; Fli1; Keratinocytes; Systemic sclerosis

Indexed keywords

CATHEPSIN V; FLI1 PROTEIN; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MAJOR CLINICAL STUDY; MICROVASCULAR ENDOTHELIAL CELL; PERICYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; DISEASE PROGRESSION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-FLI-1; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84876699983     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes379     Document Type: Article

References (44)

1. Distler J, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology 2006; 45(Suppl. 3): iii26-7.
2. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010; 14: 1241-54.
3. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010; 37: 11-25.
4. Lutgens S, Cleutjens K, Daemen M, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007; 21: 3029-41.
5. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289: 567-72.
6. D'Alessio S, Fibbi G, Cinelli M et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004; 50: 3275-85.
7. Noda S, Asano Y, Akamata K et al. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 2012; 7: e32272.
8. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010; 120: 3421-31.
9. LeRoy E, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
11. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
12. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 1994; 37: 391-4.
13. Noda S, Asano Y, Aozasa N et al. Serum Tie2 levels: clinical association with microangiopathies in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2011; 25: 1476-9.
14. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-6.
15. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
16. Asano Y, Stawski L, Hant F et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-98.
17. Asano Y, Trojanowska M. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol 2009; 29: 1882-94.
18. Hervé-Grépinet V, Veillard F, Godat E, Heuzé-Vourc'h N, Lecaille F, Lalmanach G. Extracellular catalase activity protects cysteine cathepsins from inactivation by hydrogen peroxide. FEBS Lett 2008; 582: 1307-12.
19. Bujor AM, Asano Y, Haines P, Lafyatis R, Trojanowska M. The c-Abl tyrosine kinase controls protein kinase Cd-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 2011; 63: 1729-37.
20. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115: 3589-97.
21. Cheng T, Tjabringa GS, van Vlijmen-Willems IM et al. The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis. Br J Dermatol 2009; 161: 253-64.
22. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 2005; 175: 7708-18.
23. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005; 52: 2897-905.
24. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006; 168: 499-510.
25. Kubo M, Czuwara-Ladykowska J, Moussa O et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-81.
26. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-9.
27. Spira D, Stypmann J, Tobin D et al. Cell type-specific functions of the lysosomal protease cathepsin L in the heart. J Biol Chem 2007; 282: 37045-52.
28. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 542-7.
29. Marneros AG, Olsen BR. Physiological role of collagen XVIII and endostatin. FASEB J 2005; 19: 716-28.
30. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
31. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
32. Puzer L, Barros N, Paschoalin T et al. Cathepsin V, but not cathepsins L, B and K, may release angiostatin-like fragments from plasminogen. Biol Chem 2008; 389: 195-200.
33. Ma DH, Yao JY, Kuo MT et al. Generation of endostatin by matrix metalloproteinase and cathepsin from human limbocorneal epithelial cells cultivated on amniotic membrane. Invest Ophthalmol Vis Sci 2007; 48: 644-51.
34. Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 2009; 33: 638-44.
35. Szekanecz Z, Koch AE. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 2009; 51: 1-7.
36. Bellini MH, Coutinho EL, Filgueiras TC, Maciel TT, Schor N. Endostatin expression in the murine model of ischaemia/reperfusion-induced acute renal failure. Nephrology 2007; 12: 459-65.
37. Emara M, Obaid L, Johnson S, Bigam DL, Cheung PY. Expression of angiostatin and its related factors in the plasma of newborn pigs with hypoxia and reoxygenation. Arch Biochem Biophys 2007; 466: 136-44.
38. Emara M, Obaid L, Johnson S, Bigam DL, Cheung PY. The effect of hypoxia on plasma angiostatin and related factors in newborn pigs. Proc West Pharmacol Soc 2007; 50: 47-52.
39. Distler O, Del Rosso A, Giacomelli R et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4: R11.
40. Yamasaki M, Kapanadze B, Markiewicz M, Trojanowska M. Down-regulation of Fli1 in human microvascular endothelial cells promotes cell survival and leads to cord formation in 3D collagen gels. In: Proceedings of Miami Nature Biotechnology Winter Symposium. The Cell Cycle, Chromosomes and Cancer, Miami, Florida, USA 2006. http://www.med.miami.edu/mnbws/documents/06Yamasaki.pdf (21 July 2012, date last accessed).
41. Brideau G, Mäkinen MJ, Elamaa H et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007; 67: 11528-35.
42. Aden N, Shiwen X, Aden D et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology 2008; 47: 1754-60.
43. Aden N, Nuttall A, Shiwen X et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. J Invest Dermatol 2010; 130: 2191-200.
44. Reinheckel T, Hagemann S, Dollwet-Mack S et al. The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci 2005; 118: 3387-95.